Grifols, S.A. (NASDAQ:GRFS) Shares Bought by Capital World Investors

Capital World Investors boosted its position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,134,230 shares of the biotechnology company's stock after purchasing an additional 154,358 shares during the quarter. Capital World Investors owned about 3.07% of Grifols worth $157,239,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. HighTower Advisors LLC grew its stake in Grifols by 12.5% during the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company's stock valued at $123,000 after purchasing an additional 1,546 shares during the last quarter. Stifel Financial Corp purchased a new position in Grifols during the third quarter worth approximately $1,043,000. Jane Street Group LLC acquired a new stake in Grifols during the third quarter worth about $363,000. Barclays PLC grew its holdings in shares of Grifols by 381.2% during the 3rd quarter. Barclays PLC now owns 592,552 shares of the biotechnology company's stock worth $5,261,000 after purchasing an additional 469,401 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Grifols by 56.1% during the 3rd quarter. Geode Capital Management LLC now owns 110,532 shares of the biotechnology company's stock worth $982,000 after purchasing an additional 39,733 shares during the period.

Analyst Ratings Changes

Separately, Morgan Stanley began coverage on shares of Grifols in a research report on Wednesday, February 12th. They set an "overweight" rating for the company.

Grifols Stock Performance

GRFS traded up $0.01 during trading on Wednesday, reaching $7.19. The company's stock had a trading volume of 1,146,166 shares, compared to its average volume of 1,206,278. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. Grifols, S.A. has a 52-week low of $5.79 and a 52-week high of $9.96. The company's fifty day moving average price is $7.48 and its 200-day moving average price is $7.78. The company has a market capitalization of $4.94 billion, a price-to-earnings ratio of 6.15 and a beta of 0.41.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.